secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2026-02-24T23:59:59+00:00
Accession:  0001213900-26-019639
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adial Pharmaceuticals regains Nasdaq minimum bid price compliance; highlights advanced AD04 partnering discussions
--------------------------------------------------------------------------------

- Received Nasdaq notice on Feb. 23, 2026 that closing bid price was ≥$1.00 for 10 consecutive business days (Feb. 6-20, 2026).
- Nasdaq confirmed compliance with Listing Rule 5550(a)(2) and closed the matter.
- CEO Cary Claiborne stated the company is engaged in advanced strategic partnering discussions for AD04.
- AD04 is a genetically targeted serotonin-3 receptor antagonist for Alcohol Use Disorder, moving toward Phase 3 program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390026019639/0001213900-26-019639-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390026019639/ea0278114-8k_adial.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-019639

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer